Header Logo

Connection

ELIAS JOSEPH JABBOUR to Drug Resistance, Neoplasm

Back to Details
This is a "connection" page, showing publications ELIAS JOSEPH JABBOUR has written about Drug Resistance, Neoplasm.
ELIAS JOSEPH JABBOUR
Connection Strength
4.964
Drug Resistance, Neoplasm
  1. Ultra-accurate Duplex Sequencing for the assessment of pretreatment ABL1 kinase domain mutations in Ph+ ALL. Blood Cancer J. 2020 05 26; 10(5):61.
    View in: PubMed
    Score: 0.276
  2. Impact of minimal residual disease status in patients with relapsed/refractory acute lymphoblastic leukemia treated with inotuzumab ozogamicin in the phase III INO-VATE trial. Leuk Res. 2020 01; 88:106283.
    View in: PubMed
    Score: 0.267
  3. Economic value of regular monitoring of response to treatment among US patients with chronic myeloid leukemia based on an economic model. J Med Econ. 2018 Oct; 21(10):1036-1040.
    View in: PubMed
    Score: 0.244
  4. Resistance to tyrosine kinase inhibition therapy for chronic myelogenous leukemia: a clinical perspective and emerging treatment options. Clin Lymphoma Myeloma Leuk. 2013 Oct; 13(5):515-29.
    View in: PubMed
    Score: 0.172
  5. Characteristics and outcomes of patients with V299L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors. Blood. 2012 Oct 18; 120(16):3382-3.
    View in: PubMed
    Score: 0.163
  6. Chronic myeloid leukemia: mechanisms of resistance and treatment. Hematol Oncol Clin North Am. 2011 Oct; 25(5):981-95, v.
    View in: PubMed
    Score: 0.152
  7. Results of allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia patients who failed tyrosine kinase inhibitors after developing BCR-ABL1 kinase domain mutations. Blood. 2011 Mar 31; 117(13):3641-7.
    View in: PubMed
    Score: 0.144
  8. Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations. Blood. 2009 Sep 03; 114(10):2037-43.
    View in: PubMed
    Score: 0.130
  9. Understanding the role of mutations in therapeutic decision making for chronic myeloid leukemia. Semin Hematol. 2009 Apr; 46(2 Suppl 3):S22-6.
    View in: PubMed
    Score: 0.128
  10. Suboptimal response to or failure of imatinib treatment for chronic myeloid leukemia: what is the optimal strategy? Mayo Clin Proc. 2009 02; 84(2):161-9.
    View in: PubMed
    Score: 0.126
  11. Treatment selection after imatinib resistance in chronic myeloid leukemia. Target Oncol. 2009 Jan; 4(1):3-10.
    View in: PubMed
    Score: 0.126
  12. Second-line therapy and beyond resistance for the treatment of patients with chronic myeloid leukemia post imatinib failure. Clin Lymphoma Myeloma. 2009; 9 Suppl 3:S272-9.
    View in: PubMed
    Score: 0.125
  13. Allogeneic stem cell transplantation for patients with chronic myeloid leukemia and acute lymphocytic leukemia after Bcr-Abl kinase mutation-related imatinib failure. Blood. 2006 Aug 15; 108(4):1421-3.
    View in: PubMed
    Score: 0.104
  14. Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials. Leukemia. 2024 Mar; 38(3):475-481.
    View in: PubMed
    Score: 0.089
  15. An Update on the Management of Advanced Phase Chronic Myeloid Leukemia. Curr Hematol Malig Rep. 2023 Dec; 18(6):234-242.
    View in: PubMed
    Score: 0.087
  16. The outcomes of patients with chronic myeloid leukemia treated with third-line BCR::ABL1 tyrosine kinase inhibitors. Am J Hematol. 2023 04; 98(4):658-665.
    View in: PubMed
    Score: 0.083
  17. Chronic myeloid leukemia: 2022 update on diagnosis, therapy, and monitoring. Am J Hematol. 2022 Sep; 97(9):1236-1256.
    View in: PubMed
    Score: 0.080
  18. Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia. J Clin Oncol. 2021 09 01; 39(25):2768-2778.
    View in: PubMed
    Score: 0.074
  19. Leukemia stemness and co-occurring mutations drive resistance to IDH inhibitors in acute myeloid leukemia. Nat Commun. 2021 05 10; 12(1):2607.
    View in: PubMed
    Score: 0.074
  20. The clinical development of antibody-drug conjugates - lessons from leukaemia. Nat Rev Clin Oncol. 2021 07; 18(7):418-433.
    View in: PubMed
    Score: 0.073
  21. Patterns of Resistance Differ in Patients with Acute Myeloid Leukemia Treated with Type I versus Type II FLT3 inhibitors. Blood Cancer Discov. 2021 03; 2(2):125-134.
    View in: PubMed
    Score: 0.072
  22. Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study. Cancer Discov. 2019 03; 9(3):370-383.
    View in: PubMed
    Score: 0.062
  23. Chemoimmunotherapy with inotuzumab ozogamicin combined with mini-hyper-CVD, with or without blinatumomab, is highly effective in patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in first salvage. Cancer. 2018 10 15; 124(20):4044-4055.
    View in: PubMed
    Score: 0.062
  24. Incorporating Immunotherapy Into the Treatment Strategies of B-Cell Adult Acute Lymphoblastic Leukemia: The Role of Blinatumomab and Inotuzumab Ozogamicin. Am Soc Clin Oncol Educ Book. 2018 May 23; 38:574-578.
    View in: PubMed
    Score: 0.060
  25. Chronic myeloid leukemia: 2018 update on diagnosis, therapy and monitoring. Am J Hematol. 2018 03; 93(3):442-459.
    View in: PubMed
    Score: 0.059
  26. Salvage Chemoimmunotherapy With Inotuzumab Ozogamicin Combined With Mini-Hyper-CVD for Patients With Relapsed or Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Phase 2 Clinical Trial. JAMA Oncol. 2018 Feb 01; 4(2):230-234.
    View in: PubMed
    Score: 0.059
  27. Efficacy and safety analysis by age cohort of inotuzumab ozogamicin in patients with relapsed or refractory acute lymphoblastic leukemia enrolled in INO-VATE. Cancer. 2018 04 15; 124(8):1722-1732.
    View in: PubMed
    Score: 0.059
  28. Outcome of patients with relapsed/refractory acute lymphoblastic leukemia after blinatumomab failure: No change in the level of CD19 expression. Am J Hematol. 2018 03; 93(3):371-374.
    View in: PubMed
    Score: 0.058
  29. Safety and Efficacy of Blinatumomab in Combination With a Tyrosine Kinase Inhibitor for the Treatment of Relapsed Philadelphia Chromosome-positive Leukemia. Clin Lymphoma Myeloma Leuk. 2017 Dec; 17(12):897-901.
    View in: PubMed
    Score: 0.057
  30. Treatment of adult acute lymphoblastic leukemia with inotuzumab ozogamicin. Future Oncol. 2017 Oct; 13(25):2233-2242.
    View in: PubMed
    Score: 0.057
  31. A phase I/II randomized trial of clofarabine or fludarabine added to idarubicin and cytarabine for adults with relapsed or refractory acute myeloid leukemia. Leuk Lymphoma. 2018 04; 59(4):813-820.
    View in: PubMed
    Score: 0.057
  32. Outcomes of adults with relapsed or refractory Burkitt and high-grade B-cell leukemia/lymphoma. Am J Hematol. 2017 06; 92(6):E114-E117.
    View in: PubMed
    Score: 0.056
  33. Novel Approaches for the Interim Management of Relapsed/Refractory Acute Lymphocytic Leukemia: A Case-Study Compendium. Clin Adv Hematol Oncol. 2016 Mar; 14(3 Suppl 4):1-23.
    View in: PubMed
    Score: 0.051
  34. Chronic myeloid leukemia: 2016 update on diagnosis, therapy, and monitoring. Am J Hematol. 2016 Feb; 91(2):252-65.
    View in: PubMed
    Score: 0.051
  35. Chronic myeloid leukemia: First-line drug of choice. Am J Hematol. 2016 Jan; 91(1):59-66.
    View in: PubMed
    Score: 0.051
  36. Phase II trial of ponatinib in patients with chronic myeloid leukemia resistant to one previous tyrosine kinase inhibitor. Haematologica. 2015 Dec; 100(12):e494-5.
    View in: PubMed
    Score: 0.050
  37. Jumping Translocations in Myeloid Malignancies Associated With Treatment Resistance and Poor Survival. Clin Lymphoma Myeloma Leuk. 2015 Sep; 15(9):556-62.
    View in: PubMed
    Score: 0.049
  38. Selecting the best frontline treatment in chronic myeloid leukemia. Curr Hematol Malig Rep. 2015 Jun; 10(2):145-57.
    View in: PubMed
    Score: 0.049
  39. Which tyrosine-kinase inhibitor to use first in chronic phase chronic myelogenous leukemia? Expert Opin Pharmacother. 2015 May; 16(7):999-1007.
    View in: PubMed
    Score: 0.048
  40. BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia. Cancer Cell. 2014 Sep 08; 26(3):428-442.
    View in: PubMed
    Score: 0.046
  41. Allogeneic stem cell transplantation as initial salvage for patients with acute myeloid leukemia refractory to high-dose cytarabine-based induction chemotherapy. Am J Hematol. 2014 Apr; 89(4):395-8.
    View in: PubMed
    Score: 0.045
  42. Tyrosine kinase inhibition: a therapeutic target for the management of chronic-phase chronic myeloid leukemia. Expert Rev Anticancer Ther. 2013 Dec; 13(12):1433-52.
    View in: PubMed
    Score: 0.044
  43. Prediction of outcomes in patients with Ph+ chronic myeloid leukemia in chronic phase treated with nilotinib after imatinib resistance/intolerance. Leukemia. 2013 Apr; 27(4):907-13.
    View in: PubMed
    Score: 0.041
  44. Chronic myeloid leukemia: 2012 update on diagnosis, monitoring, and management. Am J Hematol. 2012 Nov; 87(11):1037-45.
    View in: PubMed
    Score: 0.041
  45. Tyrosine kinase inhibitors in acute and chronic leukemias. Expert Opin Pharmacother. 2012 May; 13(7):927-38.
    View in: PubMed
    Score: 0.039
  46. Outcome of treatment of chronic myeloid leukemia with second-generation tyrosine kinase inhibitors after imatinib failure. Clin Lymphoma Myeloma Leuk. 2011 Jun; 11 Suppl 1:S101-10.
    View in: PubMed
    Score: 0.037
  47. Dasatinib combined with interferon-alfa induces a complete cytogenetic response and major molecular response in a patient with chronic myelogenous leukemia harboring the T315I BCR-ABL1 mutation. Clin Lymphoma Myeloma Leuk. 2011 Jun; 11 Suppl 1:S111-3.
    View in: PubMed
    Score: 0.037
  48. Minimal cross-intolerance with nilotinib in patients with chronic myeloid leukemia in chronic or accelerated phase who are intolerant to imatinib. Blood. 2011 May 26; 117(21):5600-6.
    View in: PubMed
    Score: 0.037
  49. Mutant BCR-ABL clones in chronic myeloid leukemia. Haematologica. 2011 Mar; 96(3):347-9.
    View in: PubMed
    Score: 0.036
  50. New developments in the treatment of chronic myeloid leukemia and Philadelphia-positive acute lymphoblastic leukemia. Leuk Lymphoma. 2011 Feb; 52 Suppl 1:81-91.
    View in: PubMed
    Score: 0.036
  51. Practical advice for determining the role of BCR-ABL mutations in guiding tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia. Cancer. 2011 May 01; 117(9):1800-11.
    View in: PubMed
    Score: 0.036
  52. Nilotinib for the treatment of Philadelphia-chromosome-positive chronic myeloid leukemia. Expert Opin Pharmacother. 2010 Dec; 11(18):3065-72.
    View in: PubMed
    Score: 0.036
  53. Chronic myeloid leukemia and second-generation tyrosine kinase inhibitors: when, how, and which one? Semin Hematol. 2010 Oct; 47(4):344-53.
    View in: PubMed
    Score: 0.035
  54. Treatment of Philadelphia-positive acute lymphocytic leukemia with tyrosine kinase inhibitors: What is the optimal regimen? Am J Hematol. 2010 Mar; 85(3):158-9.
    View in: PubMed
    Score: 0.034
  55. Choosing the best treatment strategy for chronic myeloid leukemia patients resistant to imatinib: weighing the efficacy and safety of individual drugs with BCR-ABL mutations and patient history. Leukemia. 2010 Jan; 24(1):6-12.
    View in: PubMed
    Score: 0.033
  56. Predictors of primary imatinib resistance in chronic myelogenous leukemia are distinct from those in secondary imatinib resistance. J Clin Oncol. 2009 Aug 01; 27(22):3642-9.
    View in: PubMed
    Score: 0.032
  57. Nilotinib: a novel Bcr-Abl tyrosine kinase inhibitor for the treatment of leukemias. Expert Opin Investig Drugs. 2008 Jul; 17(7):1127-36.
    View in: PubMed
    Score: 0.030
  58. Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy. Blood. 2008 Jul 01; 112(1):53-5.
    View in: PubMed
    Score: 0.030
  59. Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors. Blood. 2007 Dec 01; 110(12):4005-11.
    View in: PubMed
    Score: 0.029
  60. Dasatinib for the treatment of Philadelphia chromosome-positive leukaemias. Expert Opin Investig Drugs. 2007 May; 16(5):679-87.
    View in: PubMed
    Score: 0.028
  61. Optimal first-line treatment of chronic myeloid leukemia. How to use imatinib and what role for newer drugs? Oncology (Williston Park). 2007 May; 21(6):653-62; discussion 663-4, 667-8.
    View in: PubMed
    Score: 0.028
  62. Introduction: chronic myelogenous leukemia (CML). Semin Hematol. 2007 Jan; 44(1 Suppl 1):S1-3.
    View in: PubMed
    Score: 0.027
  63. New targeted therapies for chronic myelogenous leukemia: opportunities to overcome imatinib resistance. Semin Hematol. 2007 Jan; 44(1 Suppl 1):S25-31.
    View in: PubMed
    Score: 0.027
  64. Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation treated in the pre- and post-ponatinib era. Am J Hematol. 2023 10; 98(10):1619-1626.
    View in: PubMed
    Score: 0.021
  65. Ponatinib after failure of second-generation tyrosine kinase inhibitor in resistant chronic-phase chronic myeloid leukemia. Am J Hematol. 2022 11; 97(11):1419-1426.
    View in: PubMed
    Score: 0.020
  66. Ponatinib for the treatment of adult patients with resistant or intolerant Chronic-Phase Chronic Myeloid Leukemia. Expert Opin Pharmacother. 2022 May; 23(7):751-758.
    View in: PubMed
    Score: 0.020
  67. Intracranial hypertension associated with BCR-ABL1 tyrosine kinase inhibitors in chronic myeloid leukemia. Leuk Lymphoma. 2022 07; 63(7):1714-1717.
    View in: PubMed
    Score: 0.020
  68. Inotuzumab Ozogamicin for Relapsed/Refractory Acute Lymphoblastic Leukemia in the INO-VATE Trial: CD22 Pharmacodynamics, Efficacy, and Safety by Baseline CD22. Clin Cancer Res. 2021 05 15; 27(10):2742-2754.
    View in: PubMed
    Score: 0.018
  69. Impact of number of cycles on outcomes of patients with relapsed or refractory acute lymphoblastic leukaemia treated with inotuzumab ozogamicin. Br J Haematol. 2020 11; 191(3):e77-e81.
    View in: PubMed
    Score: 0.018
  70. Recent Advances in Managing Acute Lymphoblastic Leukemia. Am Soc Clin Oncol Educ Book. 2020 May; 40:330-342.
    View in: PubMed
    Score: 0.017
  71. Maintenance therapy in AML: The past, the present and the future. Am J Hematol. 2019 11; 94(11):1254-1265.
    View in: PubMed
    Score: 0.016
  72. Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study. Cancer. 2019 07 15; 125(14):2474-2487.
    View in: PubMed
    Score: 0.016
  73. A phase II study of omacetaxine mepesuccinate for patients with higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia after failure of hypomethylating agents. Am J Hematol. 2019 01; 94(1):74-79.
    View in: PubMed
    Score: 0.016
  74. Final results of a phase 2, open-label study of indisulam, idarubicin, and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome. Cancer. 2018 07 01; 124(13):2758-2765.
    View in: PubMed
    Score: 0.015
  75. Results of second salvage therapy in 673 adults with acute myelogenous leukemia treated at a single institution since 2000. Cancer. 2018 06 15; 124(12):2534-2540.
    View in: PubMed
    Score: 0.015
  76. Patient-reported outcomes from a phase 3 randomized controlled trial of inotuzumab ozogamicin versus standard therapy for relapsed/refractory acute lymphoblastic leukemia. Cancer. 2018 05 15; 124(10):2151-2160.
    View in: PubMed
    Score: 0.015
  77. A Phase II Study of Coltuximab Ravtansine (SAR3419) Monotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk. 2016 Mar; 16(3):139-45.
    View in: PubMed
    Score: 0.013
  78. The role of ponatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia. Expert Rev Anticancer Ther. 2015 Apr; 15(4):365-73.
    View in: PubMed
    Score: 0.012
  79. Phase I trial of SAR103168, a novel multi-kinase inhibitor, in patients with refractory/relapsed acute leukemia or high-risk myelodysplastic syndrome. Leuk Lymphoma. 2015 Feb; 56(2):395-400.
    View in: PubMed
    Score: 0.012
  80. Advances in the treatment of relapsed/refractory acute lymphoblastic leukemia: a case study compendium. Clin Adv Hematol Oncol. 2014 Dec; 12(12 Suppl 20):8-18, 1.
    View in: PubMed
    Score: 0.012
  81. Outcome after failure of second generation tyrosine kinase inhibitors treatment as first-line therapy for patients with chronic myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2013 Aug; 13(4):477-84.
    View in: PubMed
    Score: 0.011
  82. Allogeneic stem cell transplantation for chronic myeloid leukemia resistant to tyrosine kinase inhibitors. Clin Lymphoma Myeloma Leuk. 2011 Jun; 11 Suppl 1:S96-100.
    View in: PubMed
    Score: 0.009
  83. Outcome of patients with chronic myeloid leukemia with multiple ABL1 kinase domain mutations receiving tyrosine kinase inhibitor therapy. Haematologica. 2011 Jun; 96(6):918-21.
    View in: PubMed
    Score: 0.009
  84. Rapid clonal shifts in response to kinase inhibitor therapy in chronic myelogenous leukemia are identified by quantitation mutation assays. Cancer Sci. 2010 Sep; 101(9):2005-10.
    View in: PubMed
    Score: 0.009
  85. Uncommon BCR-ABL kinase domain mutations in kinase inhibitor-resistant chronic myelogenous leukemia and Ph+ acute lymphoblastic leukemia show high rates of regression, suggesting weak selective effects. Blood. 2010 Jul 01; 115(26):5428-9.
    View in: PubMed
    Score: 0.009
  86. Standard management of patients with chronic myeloid leukemia. Clin Lymphoma Myeloma. 2009; 9 Suppl 4:S382-90.
    View in: PubMed
    Score: 0.008
  87. Kinase domain point mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia emerge after therapy with BCR-ABL kinase inhibitors. Cancer. 2008 Sep 01; 113(5):985-94.
    View in: PubMed
    Score: 0.008
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.